For millions of Americans, generic medications represent more than a lower-cost alternative to brand-name prescriptions. They are the foundation of daily healthcare, providing treatment for chronic illnesses, heart disease, cancer recovery, diabetes, and countless other conditions that require consistent access to safe, effective medication.
Yet as national conversations continue to focus on healthcare affordability, another issue has increasingly moved into the spotlight: quality.
That issue will take center stage in Washington as New Jersey patient advocate Lisa Salberg, founder and chief executive officer of the Hypertrophic Cardiomyopathy Association (HCMA), prepares to testify before the United States Senate Special Committee on Aging regarding generic drug quality, patient safety, and the growing concerns many patients and physicians have raised about consistency across the pharmaceutical supply chain.
For New Jersey, Salberg’s appearance represents far more than another congressional hearing. It places one of the state’s most recognized patient advocates at the center of a national healthcare discussion that affects virtually every family in America.
The testimony comes at a time when healthcare providers, regulators, lawmakers, patient organizations, and consumers are increasingly examining how medications are manufactured, tested, distributed, and monitored. While generic drugs have become an essential component of modern healthcare systems by helping lower costs and expand access, questions surrounding manufacturing standards, international supply chains, quality control, and patient outcomes continue to generate debate among policymakers.
Salberg’s perspective carries particular weight because her advocacy is grounded in decades of direct engagement with patients and families facing life-threatening cardiovascular conditions.
As founder of the Hypertrophic Cardiomyopathy Association, a New Jersey-based organization that has grown into one of the world’s leading patient advocacy groups focused on hypertrophic cardiomyopathy, Salberg has spent years helping patients navigate complex medical decisions, treatment plans, insurance challenges, and medication concerns.
Hypertrophic cardiomyopathy, often referred to as HCM, is one of the most common inherited heart diseases, affecting hundreds of thousands of individuals in the United States. The condition can cause abnormal thickening of the heart muscle, potentially leading to serious complications including heart failure, arrhythmias, stroke, and sudden cardiac events.
For patients living with HCM and other chronic illnesses, consistency in medication quality is not merely a regulatory issue. It is a matter of health, stability, and, in some cases, survival.
That reality has placed Salberg among the most respected voices in the patient advocacy community.
Over the years, she has become a leading advocate for greater transparency in healthcare, expanded patient education, improved access to treatment, and stronger patient representation in policy discussions. Her work has helped elevate the experiences of individuals who often find themselves navigating complex healthcare systems while managing serious medical conditions.
Now, those experiences are being brought directly before federal lawmakers.
The Senate hearing arrives during a period of heightened national attention on pharmaceutical manufacturing and oversight.
The generic drug market has transformed dramatically over the last several decades. Today, generic medications account for the overwhelming majority of prescriptions dispensed in the United States. They have helped reduce healthcare costs for patients, insurers, employers, and government healthcare programs while expanding access to treatment for millions of Americans.
The economic impact has been substantial.
Without generic medications, healthcare costs would be significantly higher across virtually every sector of the healthcare system. Patients who rely on daily medications for heart disease, hypertension, cholesterol management, diabetes, mental health conditions, and other chronic illnesses would face dramatically increased financial burdens.
At the same time, growing reliance on global manufacturing networks has created new challenges.
Many active pharmaceutical ingredients and finished medications now originate from facilities located outside the United States. While federal oversight mechanisms remain in place, healthcare experts and patient advocates have increasingly raised questions about inspection processes, manufacturing consistency, supply chain vulnerabilities, and quality assurance standards.
These concerns intensified during recent years as global disruptions exposed weaknesses in pharmaceutical supply networks and highlighted the importance of maintaining reliable access to critical medications.
For patients managing chronic conditions, even small variations in drug formulation, effectiveness, availability, or manufacturing practices can generate anxiety and uncertainty.
Patient advocacy groups have documented instances in which individuals reported differences in therapeutic outcomes after switching between manufacturers. While regulators maintain rigorous approval standards for generic medications, patient organizations continue to push for greater transparency and additional research into long-term quality consistency.
Salberg’s testimony is expected to bring those patient experiences into the policy conversation.
Rather than focusing solely on technical regulatory frameworks, patient advocates often emphasize the human impact behind healthcare decisions. They argue that discussions about drug quality should include the perspectives of those who depend on medications every day.
That patient-centered approach has defined Salberg’s advocacy throughout her career.
The HCMA itself has become a model for how patient organizations can influence healthcare policy, research priorities, and public awareness. Founded in New Jersey, the organization has grown from a grassroots initiative into an internationally recognized resource connecting patients, physicians, researchers, caregivers, and policymakers.
Its success reflects a broader tradition of healthcare leadership emerging from New Jersey.
The Garden State occupies a unique position within the healthcare ecosystem. Home to major pharmaceutical companies, research institutions, academic medical centers, biotechnology firms, and patient advocacy organizations, New Jersey plays an outsized role in shaping healthcare innovation and policy discussions nationwide.
Many of the treatments, therapies, and medical breakthroughs influencing healthcare globally have roots in New Jersey laboratories, hospitals, universities, and research centers.
Equally important, many of the advocates ensuring patient voices remain part of those conversations also call New Jersey home.
Salberg’s upcoming testimony highlights that legacy.
Her appearance before the Senate Committee on Aging underscores the growing recognition that healthcare policy cannot be shaped solely by regulators, manufacturers, and lawmakers. Patients themselves must remain active participants in discussions affecting the medications they take, the treatments they receive, and the healthcare systems they depend upon.
The committee’s focus on aging populations further reinforces the significance of the issue.
Older Americans consume a substantial percentage of prescription medications nationwide, making them particularly vulnerable to disruptions in drug availability, affordability, and quality. As the nation’s population continues aging, ensuring confidence in generic medications becomes increasingly important from both a public health and economic perspective.
Healthcare experts frequently note that maintaining trust in generic medications is essential to preserving the broader healthcare system’s ability to manage costs while ensuring access to treatment.
That trust depends not only on affordability but also on confidence.
Patients must believe that the medications they receive meet consistent standards for safety, quality, and effectiveness regardless of where they are manufactured or distributed.
As lawmakers continue examining the future of pharmaceutical oversight, supply chain resilience, and patient protections, voices like Salberg’s provide a critical perspective often missing from purely technical policy discussions.
Her testimony represents the experiences of patients who live every day with complex medical conditions and who rely on medications not as abstract policy concepts but as essential tools for managing their health and improving their quality of life.
For New Jersey, it is another example of the state’s continuing influence on national healthcare conversations.
For patients across the country, it is an opportunity to ensure that discussions about generic drug quality remain focused on the people ultimately affected by those decisions.
And for policymakers in Washington, it serves as a reminder that behind every regulatory framework, manufacturing standard, and pharmaceutical policy debate are real individuals whose health outcomes depend upon the decisions being made.
As Lisa Salberg takes her seat before the Senate Committee on Aging, she will carry with her not only the perspective of a nationally respected advocate, but also the voices of countless patients who believe that affordability, accessibility, and quality must remain inseparable components of American healthcare.
